8-K: Calidi Biotherapeutics Reports First Quarter 2024 Results and Corporate Updates

Calidi Biotherapeutics announced its first quarter 2024 financial results, highlighted clinical and preclinical advancements, and detailed a recent $6.1 million capital raise.

Summary

• Calidi Biotherapeutics reported a net loss of $7.2 million, or $0.20 per share, for the first quarter of 2024, compared to a net loss of $6.5 million, or $0.75 per share, for the same period in 2023.
• Research and development expenses were $2.7 million, slightly up from $2.6 million in the first quarter of 2023.
• General and administrative expenses increased to $4.0 million from $2.8 million in the same period last year.
• The company's cash position decreased to approximately $1.2 million as of March 31, 2024, from $1.9 million at the end of 2023.
• Calidi completed a public offering of 15,197,500 shares and warrants, raising gross proceeds of $6.1 million.
• The company plans to present three posters at the ASCO Annual Meeting, including an update on the Phase 1 trial for CLD-101 in recurrent high-grade glioma.
• Calidi also unveiled its RTNova systemic platform, designed for ease of administration and targeting multiple tumor types.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive clinical advancements and a successful capital raise, but the increasing losses and decreasing cash balance raise concerns about the company's financial stability.

Positives

• Calidi successfully raised $6.1 million through a public offering, strengthening its balance sheet.
• The company is advancing its clinical programs with upcoming presentations at the ASCO Annual Meeting.
• Calidi has developed the RTNova systemic platform, which has the potential to target diverse tumor types.
• Preclinical data supports the use of stem cells to protect and enhance antitumor virotherapies.

Negatives

• The company's net loss increased to $7.2 million in Q1 2024 from $6.5 million in Q1 2023.
• General and administrative expenses increased significantly to $4.0 million from $2.8 million year-over-year.
• Calidi's cash balance decreased to $1.2 million, indicating a need for further capital raising.
• The company is reliant on raising additional capital to advance its clinical trials.

Risks

• Calidi faces the risk of not being able to raise sufficient capital to support its clinical trials.
• Early clinical trial results may not predict final outcomes, and results may change as more data becomes available.
• There is a risk that Calidi may not receive FDA approval for its therapeutic candidates.
• The company's financial position is weak with a low cash balance and increasing losses.

Future Outlook

The company anticipates an interim clinical update from its ongoing Phase 1 trial and the initiation of a Phase 1 trial with Northwestern University in the third quarter of 2024, subject to additional capital being raised.

Management Comments

• Allan Camaisa, CEO and Chairman of the Board, stated that Calidi plans to present three posters at ASCO, including an update from their ongoing trial with City of Hope.
• Mr. Camaisa also noted that Calidi has strengthened its preclinical programs, unveiled a novel systemic delivery platform, and executed a capital raise.

Industry Context

This announcement reflects the ongoing challenges and progress in the immuno-oncology sector, where companies are focused on developing novel therapies and securing funding for clinical trials. Calidi's focus on virotherapies and stem cell-based delivery aligns with current trends in the field.

Comparison to Industry Standards

• Calidi's cash burn rate is concerning compared to other clinical-stage biotech companies, many of which have a cash runway of at least 12 months.
• The increase in general and administrative expenses is higher than the industry average for companies at a similar stage of development.
• The $6.1 million capital raise is relatively small compared to the funding needs of other companies in the sector, such as companies like Iovance Biotherapeutics or Adaptimmune, which have raised significantly larger amounts.
• The company's focus on novel delivery platforms is similar to other companies in the space, such as Oncolytics Biotech, but Calidi's technology is still in early stages of development.

Stakeholder Impact

• Shareholders may be concerned about the increasing losses and decreasing cash balance.
• Employees may be impacted by potential cost-cutting measures.
• Customers (patients) may benefit from the advancement of Calidi's therapeutic candidates.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Calidi plans to present three posters at the ASCO Annual Meeting.
• The company anticipates an interim clinical update from its ongoing Phase 1 trial.
• Calidi plans to initiate a Phase 1 trial with Northwestern University in the third quarter of 2024, subject to additional capital being raised.

Key Dates

Keywords

biotherapeutics, immunotherapy, virotherapy, oncology, clinical trials, cancer, stem cells, RTNova, capital raise, ASCO